Patents Assigned to The United States of America as represented by the Secretary, Department of Health and Human Services
  • Patent number: 10703816
    Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: July 7, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. Mackall
  • Patent number: 10703746
    Abstract: Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: July 7, 2020
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Matthew Brian Boxer, Jason Matthew Rohde, Rajan Pragani, Li Liu, Mindy Irene Emily Davis, Kyle Ryan Brimacombe, Min Shen, Anton Simeonov, Surendra Karavadhi, Daniel Jason Urban, Ajit Jadhav, Xiaodong Wang, Andrew Louis McIver
  • Patent number: 10703708
    Abstract: The present invention concerns a method of synthesizing a iodo- or astatoarene comprising the reaction of a diaryliodonium compound with a iodide or astatide salt, respectively. The invention also relates to said iodo- or astatoarene and diaryliodonium compound as such. The invention also concerns a method of synthesizing a iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoarene.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: July 7, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, UNIVERSITE D'ANGERS, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: François Guerard, Jean-François Gestin, Martin W. Brechbiel, Yong-Sok Lee
  • Publication number: 20200206441
    Abstract: A nasal delivery device can include a nasal prong and an activation member. The nasal prong can have an opening at a top and bottom portion of the prong to allow for the passage of an aerosolized treatment agent through the nasal prong. The activation member can be positioned on the nasal delivery device at a location that is spaced apart from the subject's oral cavity when the nasal prong is received into the nostril of the subject. The activation member can detect a desired exhalation state of the subject and upon detection of the desired exhalation state, the activation member activates the delivery of the aerosolized treatment agent.
    Type: Application
    Filed: February 21, 2020
    Publication date: July 2, 2020
    Applicants: The United States of America, as represented by the Secretary, Department of Health & Human Services, Creare LLC
    Inventors: Mark J. Papania, James J. Barry, Mark C. Bagley, James Norris, Darin A. Knaus, Eric M. Friets
  • Patent number: 10697028
    Abstract: Disclosed herein are methods of detecting HIV-1 nucleic acids in a sample (such as from a sample containing or suspected to contain HIV-1 nucleic acid). In some examples, the methods include loop-mediated isothermal amplification (LAMP) or reverse transcription-LAMP (RT-LAMP). In some examples, the methods include contacting a sample with one or more sets of LAMP primers specific for HIV-1 (such as LAMP primers specific for an HIV-1 integrase nucleic acid or LAMP primers specific for an HIV-1 reverse transcriptase nucleic acid) under conditions sufficient to produce an amplification product and detecting the amplification product. Sets of LAMP primers for detection of HIV-1 integrase nucleic acids (such as SEQ ID NOs: 8-14 or 8-27) and HIV-1 reverse transcriptase nucleic acids (such as SEQ ID NOs: 1-7) are provided herein.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: June 30, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kelly A. Curtis, Sherry M. Owen, Philip Niedzwiedz, Donna L. Rudolph
  • Patent number: 10698056
    Abstract: One aspect of the present disclosure provides an imaging method including: specifying an imaging focus region on a subject to be imaged, applying radiofrequency pulses to the subject to interact with a magnetic field gradient, wherein the radiofrequency pulses successively bend magnetization phases of respective electromagnetic signals from the specified imaging focus region, resulting in magnified pixel data, and generating a magnified image of the imaging focus region based on the magnified pixel data.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 30, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventor: Jun Shen
  • Patent number: 10695540
    Abstract: Disclosed herein are embodiments of segmented metallic guidewires that are suitable for MRI catheterization. Disclosed guidewires comprise a plurality of short conductive metallic segments that individually are short enough such that they do not resonate during MRI. The conductive segments are electrically insulated from each other and mechanically coupled together end-to-end via connectors, such as stiffness matched connectors, to provide a sufficiently long, strong, and flexible guidewire for catheterization that is non-resonant during MRI.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: June 30, 2020
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Ozgur Kocaturk, Burcu Basar, Robert J. Lederman
  • Patent number: 10695414
    Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 30, 2020
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Center for Disease Control and Prevention
    Inventors: Olen M. Kew, Cara Carthel Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
  • Patent number: 10695355
    Abstract: Described herein are methods for the treatment of a human subject who has had a stroke by administering to the subject a pharmaceutical composition including an antagonist of the P2X4 receptor. The antagonist of the P2X4 receptor can be administered in the acute phase of stroke, optionally in combination with a thrombolytic therapeutic or a procedure on the subject involving a clot-removal device.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 30, 2020
    Assignees: UNIVERSITY OF CONNECTICUT, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Bruce Liang, Rajkumar Verma, Kenneth A. Jacobson
  • Patent number: 10696631
    Abstract: The present invention is directed to a compound of Formula I or Formula III or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: wherein the definitions R1-R13 and L1-L4 are provided in the disclosure, and wherein R14 is a peptide. The compounds of Formula I may be covalently bonded to a peptide via a linker to provide a compound of Formula III and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: June 30, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Xiaoyuan Chen, Orit Jacobson Weiss
  • Patent number: 10697975
    Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: June 30, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Board of Regents of the University of Nebraska, University of Rochester, Arizona Board of Regents on behalf of the University of Arizona, Universitat de Barcelona, Fundacio Clinic, Hospital Clinic de Barcelona, Julius-Maximilians-University of Würzburg, British Columbia Cancer Agency Branch, Oslo University Hospital HF, Queen Mary and Westfield College, University of London
    Inventors: Louis M. Staudt, George Wright, Sandeep Dave, Bruce Tan, John I. Powell, Wyndham Wilson, Elaine S. Jaffe, Wing C. Chan, Timothy C. Greiner, Dennis Weisenburger, James Armitage, Kai Fu, Richard I. Fisher, Lisa M. Rimsza, Thomas Miller, Thomas Grogan, Elias Campo Guerri, Silvia M. Bea, Itziar Salaverria, Armando Lopez-Guillermo, Emilio Montserrat, Victor Moreno, Andreas Zettl, German Ott, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, Julie Vose, Randy Gascoyne, Joseph Connors, Erlend B. Smeland, Stein Kvaloy, Harald Holte, Jan Delabie, T. Andrew Lister
  • Publication number: 20200199587
    Abstract: The description provides a molecular switch comprising at least two nanoparticles, wherein a first nanoparticle comprises DNA and/or RNA oligonucleotides, and a second nanoparticle which is complementary to the first nanoparticle comprises reverse complementary DNA and/or RNA oligonucleotides of the first nanoparticle; wherein the complementary nanoparticles interact under physiological conditions leading to thermodynamically driven conformational changes in the first and second nanoparticles leading to their re-association to release one or more duplexes comprising said DNA and/or RNA oligonucleotides and the reverse complementary DNA and/or RNA oligonucleotides, and wherein the nanoparticles are not rings and have no single stranded toeholds.
    Type: Application
    Filed: April 3, 2018
    Publication date: June 25, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, The University of North Carolina at Charlotte
    Inventors: Bruce Allen Shapiro, Kirill Andreevich Afonin, Eckart H.U. Bindewald, Mathias D. Viard, Wojciech Kasprzak, Marina A. Dobrovolskaia, Justin R. Halman
  • Patent number: 10687942
    Abstract: Devices and methods are disclosed for the treatment or repair of regurgitant cardiac valves, such as a mitral valve. An annuloplasty device can be placed in the coronary sinus to reshape the mitral valve and reduce mitral valve regurgitation. A protective device can be placed between the annuloplasty device and an underlying coronary artery to inhibit compression of the underlying coronary artery by the annuloplasty device in the coronary sinus. In addition, the protective device can inhibit compression of the coronary artery from inside the heart, such as from a prosthetic mitral valve that exerts radially outward pressure toward the coronary artery. The annuloplasty device can also create an artificial inner ridge or retaining feature projecting into the native mitral valve region to help secure a prosthetic mitral valve.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: June 23, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: June-Hong Kim, Robert J. Lederman, Ozgur Kocaturk
  • Patent number: 10689456
    Abstract: The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding-transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intracellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3? intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: June 23, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Qiong J. Wang, Zhiya Yu, James C. Yang
  • Patent number: 10683362
    Abstract: Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to improved recombinant immunotoxins comprising anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and a Pseudomonas Exotoxin moiety which has been modified to reduce its immunogenicity and protease sensitivity and providing a better cytotoxicity for cells which express mesothelin. The RITs are well-suited for the treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: June 16, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ira H. Pastan, John Weldon, Richard Beers
  • Patent number: 10683277
    Abstract: Described are compounds, which are antagonists of the P2Y14 receptor, for example, a compound of formula (I) in which ring A, R1, R2, R3, and n are as described herein. Also provided are dendron conjugates comprising the compounds, and methods of using the compounds, including a method of treating a disorder, such as inflammation, diabetes, insulin resistance, hyperglycemia, a lipid disorder, obesity, a condition associated with metabolic syndrome, and asthma, and a method of antagonizing P214 receptor activity in a cell.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: June 16, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kenneth A. Jacobson, Anna Junker, Elisa Uliassi, Evgeny Kiselev
  • Patent number: 10683270
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: June 16, 2020
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: George Kunos, Malliga Iyer, Resat Cinar, Kenner C. Rice
  • Patent number: 10683316
    Abstract: The invention provides for the treatment of disorders related to viral infection, using salen manganese compounds.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: June 16, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Trustees of Boston University
    Inventors: John C. Kash, Jeffery K. Taubenberger, Rodney L. Levine, Susan Doctrow
  • Patent number: 10682379
    Abstract: Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: June 16, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Ian Antheni Myles, Sandip K. Datta
  • Publication number: 20200181215
    Abstract: The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.
    Type: Application
    Filed: January 31, 2020
    Publication date: June 11, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Jeffrey Schlom, Claudia M. Palena